MedTrace Logo

Evaluate the Safety and Effectiveness of Using Echogenic Embolic Agent for Embolization of Prostate Artery for Treatment of Men With BPH (PAE CEUS)

NCT04267445 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-02-17

No results posted yet for this study

Summary

A prospective single centre study to evaluate the safety and effectiveness of using contrast enhanced ultrasound and echogenic embolic agent Ekobi Embolization Microspheres in Prostate Artery Embolization for the Treatment of Men with Benign Prostatic Hyperplasia

Conditions

  • Benign Prostatic Hyperplasia

Interventions

PROCEDURE

Embolization of prostatic artery under ultrasound guidance

Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.

Sponsors & Collaborators

  • IMBiotechnologies Ltd.

    collaborator INDUSTRY

  • University of Calgary

    lead OTHER

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2021-12-31
Completion
2023-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04267445 on ClinicalTrials.gov